Optimized sampling to estimate vancomycin drug exposure: Comparison of pharmacometric and equation-based approaches in a simulation-estimation study.


Journal

CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011

Informations de publication

Date de publication:
06 2022
Historique:
revised: 24 02 2022
received: 08 10 2021
accepted: 25 02 2022
pubmed: 9 3 2022
medline: 18 6 2022
entrez: 8 3 2022
Statut: ppublish

Résumé

Vancomycin dosing should be accompanied by area under the concentration-time curve (AUC)-guided dosing using model-informed precision dosing software according to the latest guidelines. Although a peak plus a trough sample is considered the gold standard to determine the AUC, single-sample strategies might be more economic. Yet, optimal sampling times for AUC determination of vancomycin have not been systematically evaluated. In the present study, automated one- or two-sample strategies were systematically explored to estimate the AUC with a model averaging and a model selection algorithm. Both were compared with a conventional equation-based approach in a simulation-estimation study mimicking a heterogenous patient population (n = 6000). The optimal single-sample timepoints were identified between 2-6.5 h post dose, with varying bias values between -2.9% and 1.0% and an imprecision of 23.3%-24.0% across the population pharmacokinetic approaches. Adding a second sample between 4.5-6.0 h improved the predictive performance (-1.7% to 0.0% bias, 17.6%-18.6% imprecision), although the difference in the two-sampling strategies were minor. The equation-based approach was always positively biased and hence inferior to the population pharmacokinetic approaches. In conclusion, the approaches always preferred samples to be drawn early in the profile (<6.5 h), whereas sampling of trough concentrations resulted in a higher imprecision. Furthermore, optimal sampling during the early treatment phase could already give sufficient time to individualize the second dose, which is likely unfeasible using trough sampling.

Identifiants

pubmed: 35259285
doi: 10.1002/psp4.12782
pmc: PMC9197536
doi:

Substances chimiques

Anti-Bacterial Agents 0
Vancomycin 6Q205EH1VU

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

711-720

Informations de copyright

© 2022 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.

Références

Pharmacotherapy. 2015 Feb;35(2):127-39
pubmed: 25644478
Clin Pharmacokinet. 2014 Sep;53(9):849-61
pubmed: 25117184
Clin Pharmacokinet. 2019 Mar;58(3):389-399
pubmed: 30140975
Clin Pharmacokinet. 2012 Jan 1;51(1):1-13
pubmed: 22149255
Methods Mol Biol. 2012;929:377-89
pubmed: 23007438
N Engl J Med. 2015 Jun 4;372(23):2229-34
pubmed: 26014593
Nat Rev Drug Discov. 2016 Mar;15(3):145-6
pubmed: 26669674
Clin Pharmacol Ther. 2016 Apr;99(4):405-18
pubmed: 26785109
J Antimicrob Chemother. 2020 Nov 1;75(11):3293-3302
pubmed: 32790842
Clin Pharmacol Ther. 2021 Apr;109(4):928-941
pubmed: 33565627
J Antimicrob Chemother. 2009 May;63(5):1050-7
pubmed: 19299472
Clin Pharmacol Ther. 2021 Jan;109(1):175-183
pubmed: 32996120
Clin Pharmacokinet. 2004;43(13):925-42
pubmed: 15509186
Br J Clin Pharmacol. 2020 Dec;86(12):2497-2506
pubmed: 32415710
Br J Clin Pharmacol. 2010 Aug;70(2):201-12
pubmed: 20653673
JAMA. 2014 Oct 8;312(14):1438-46
pubmed: 25291579
CPT Pharmacometrics Syst Pharmacol. 2019 May 6;:
pubmed: 31056834
Crit Care Med. 2021 Oct 1;49(10):e952-e960
pubmed: 33938713
Clin Microbiol Infect. 2019 Oct;25(10):1286.e1-1286.e7
pubmed: 30872102
N Engl J Med. 2017 Jun 8;376(23):2235-2244
pubmed: 28528569
J Antimicrob Chemother. 2016 Feb;71(2):471-9
pubmed: 26568565
Clin Microbiol Infect. 2020 Jul 13;:
pubmed: 32673799
Adv Drug Deliv Rev. 2014 Nov 20;77:50-7
pubmed: 24910345
Int J Antimicrob Agents. 2019 Apr;53(4):401-407
pubmed: 30599240
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30833424
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29203493
Antimicrob Agents Chemother. 2011 Jun;55(6):2704-9
pubmed: 21402850
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S5-12
pubmed: 16323120
Antimicrob Agents Chemother. 2014;58(1):309-16
pubmed: 24165176
Am J Health Syst Pharm. 2020 May 19;77(11):835-864
pubmed: 32191793
AAPS J. 2019 Jan 9;21(2):17
pubmed: 30627939
CPT Pharmacometrics Syst Pharmacol. 2022 Jun;11(6):711-720
pubmed: 35259285
Pharmacotherapy. 2018 Dec;38(12):1174-1183
pubmed: 30362592
Expert Rev Clin Pharmacol. 2018 Aug;11(8):743-746
pubmed: 30010447
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98
pubmed: 19106348
Front Pharmacol. 2020 Mar 03;11:172
pubmed: 32194411
Clin Infect Dis. 2020 Apr 10;70(8):1536-1545
pubmed: 31157370

Auteurs

David W Uster (DW)

Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.

Sebastian G Wicha (SG)

Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg, Hamburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH